Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Singapore
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Hernexeos (zongertinib) is the first oral targeted therapy for HER2-mutant advanced non-small cell lung cancer, offering an oral alternative to infused HER2-targeted therapies for this patient population.
Hernexeos is FDA-approved for adults with unresectable or metastatic nonsquamous NSCLC harboring HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test — both as an initial treatment option and for previously treated patients.
Zongertinib selectively blocks phosphorylation of HER2, reducing downstream signaling that drives proliferation in lung cancer cells with activating HER2 tyrosine kinase domain mutations.
The dose is weight-based: 120 mg orally once daily for patients under 90 kg (198 lb), or 180 mg orally once daily for patients 90 kg or more, taken with or without food, continued until disease progression or unacceptable toxicity, as determined by the treating oncologist.
Hernexeos requires monitoring for several important safety considerations.
Severe and life-threatening ILD/pneumonitis can occur, with a median onset around 13 weeks after starting treatment. Monitor for new or worsening dyspnea, cough, or fever, and interrupt, reduce, or discontinue treatment based on severity.
Among the most common adverse reactions. Patients should contact their treating physician promptly if diarrhea occurs.
Monitor left ventricular ejection fraction at baseline and at regular intervals during treatment, with dose adjustment as needed.
Hernexeos can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Hernexeos (zongertinib) received FDA accelerated approval in August 2025, expanded to treatment-naive patients in February 2026, and is manufactured by Boehringer Ingelheim as the first oral targeted therapy for HER2-mutant NSCLC.
Import of Hernexeos through a Named Patient Program requires a valid prescription from the treating oncologist, confirmation of HER2 tyrosine kinase domain mutation status via an FDA-approved test, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Hernexeos directly from Boehringer Ingelheim's authorized supply chain to ensure product authenticity and regulatory compliance.
Hernexeos is sourced through verified, GDP-compliant channels from Boehringer Ingelheim's authorized supply chain to ensure authenticity and quality.
Hernexeos tablets should be stored at 20°C to 25°C (68°F to 77°F), in the original bottle with the desiccants inside, and used within 3 months of first opening.
Once sourced, Hernexeos is packed and transported under appropriate temperature-controlled conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Hernexeos through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading oncology centers in Mumbai support HER2 mutation testing and treatment coordination for Hernexeos access.
Delhi's major cancer hospitals assist patients with molecular testing and prescription support for Hernexeos.
Bangalore's oncology network offers access to HER2 testing and treatment planning for eligible NSCLC patients.
Chennai-based specialists coordinate Hernexeos access alongside comprehensive lung cancer care.
Hyderabad's cancer care institutions support patients pursuing Hernexeos therapy following confirmed HER2 mutation status.
Kolkata's oncology centers help coordinate documentation and treatment access for Hernexeos.
Pune-based oncologists assist with HER2 mutation testing and Hernexeos treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Hernexeos.
Kochi's oncology units assist patients with the documentation needed for Hernexeos access.
Chandigarh's cancer care centers support Hernexeos treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Hernexeos access process.
Lucknow-based cancer centers assist patients pursuing Hernexeos therapy.
Bhubaneswar's oncology institutions support access to Hernexeos for eligible patients.
Guwahati's specialists help coordinate Hernexeos access for patients across the Northeast.
Patients in other cities across India can also access Hernexeos through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
